"The U.S. Food and Drug Administration will complete its phase-out of all inhaler medical products containing chlorofluorocarbons (CFCs) by Dec. 31, 2013. This effort is to comply with an international treaty to protect the ozone layer by phasing "...
Maxair Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Maxair (pirbuterol) inhalation is used to treat conditions such as asthma, bronchitis, and emphysema. It is a bronchodilator. Common side effects include headache, dizziness, lightheadedness, insomnia, tremor or nervousness, sweating, nausea, vomiting, or diarrhea, or dry mouth.
The usual dose of Maxair for adults and children 12 years and older is two inhalations (400 mcg) repeated every 4-6 hours. One inhalation (200 mcg) repeated every 4-6 hours may be sufficient for some patients. A total daily dose of 12 inhalations should not be exceeded. Maxair may interact with beta-blockers, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, other inhaled bronchodilators, caffeine, diet pills, or decongestants. Tell your doctor all medications you use. During pregnancy, Maxair should be used only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breast-feeding.
Our Maxair (pirbuterol) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Patient Information in Detail?
Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.
Maxair in Detail - Patient Information: Side Effects
Stop using pirbuterol and seek emergency medical attention if you experience any of the following serious side effects:
- an allergic reaction (difficulty breathing; closing of your throat; swelling of your lips, tongue, or face; or hives); or
- chest pain or irregular heartbeats.
Other, less serious side effects may be more likely to occur. Continue to use pirbuterol inhalation and talk to your doctor if you experience
- headache, dizziness, lightheadedness, or insomnia;
- tremor or nervousness;
- nausea, vomiting, or diarrhea; or
- dry mouth.
Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome. You may report side effects to FDA at 1-800-FDA-1088.
Read the entire detailed patient monograph for Maxair (Pirbuterol) »
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Maxair FDA Prescribing Information: Side Effects
The following rates of adverse reactions to pirbuterol are based on single- and multiple-dose clinical trials involving 761 patients, 400 of whom received multiple doses (mean duration of treatment was 2.5 months and maximum was 19 months).
The following were the adverse reactions reported more frequently than 1 in 100 patients:
CNS: nervousness (6.9%), tremor (6.0%), headache (2.0%), dizziness (1.2%).
Respiratory: cough (1.2%).
Gastrointestinal: nausea (1.7%).
The following adverse reactions occurred less frequently than 1 in 100 patients and there may be a causal relationship with pirbuterol:
Ear, Nose and Throat: smell/taste changes, sore throat.
Other adverse reactions were reported with a frequency of less than 1 in 100 patients but a causal relationship between pirbuterol and the reaction could not be determined: migraine, productive cough, wheezing, and dermatitis.
The following rates of adverse reactions during three-month controlled clinical trials involving 310 patients are noted. The table does not include mild reactions.
PERCENT OF PATIENTS WITH MODERATE TO SEVERE ADVERSE REACTIONS
|Central Nervous System|
Electrocardiograms: Electrocardiograms, obtained during a randomized, double-blind, crossover study in 57 patients, showed no observations or findings considered clinically significant, or related to drug administration. Most electrocardiographic observations, obtained during a randomized, double-blind, cross-over study in 40 patients, were judged not clinically significant or related to drug administration. One patient was noted to have some changes on the one hour postdose electrocardiogram consisting of ST and T wave abnormality suggesting possible inferior ischemia. This abnormality was not observed on the predose or the six hours postdose ECG. A treadmill was subsequently performed and all the findings were normal.
Read the entire FDA prescribing information for Maxair (Pirbuterol) »
Additional Maxair Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Allergies & Asthma
Improve treatments & prevent attacks.